4D Pharma PLC (LBPS) Stock Price, Quote, News and Overview
NASDAQ:LBPS - Nasdaq - US35085K1097 - ADR
LBPS Quote, Performance and Key Statistics
NASDAQ:LBPS (6/24/2022, 8:00:03 PM)
1.65
+0.04 (+2.48%)
The current stock price of LBPS is 1.65 null. In the past month the price decreased by -50%. In the past year, price decreased by -84.79%.
LBPS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 54.22 | 707.26B | ||
| JNJ | JOHNSON & JOHNSON | 14.77 | 357.16B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.01 | 290.31B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 12.86 | 211.00B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.2 | 209.96B | ||
| MRK | MERCK & CO. INC. | 9.84 | 192.83B | ||
| PFE | PFIZER INC | 7.12 | 129.71B | ||
| SNY | SANOFI-ADR | 13.25 | 122.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.35 | 94.81B | ||
| GSK | GSK PLC-SPON ADR | 6.69 | 73.55B | ||
| ZTS | ZOETIS INC | 26.65 | 71.55B | ||
| HLN | HALEON PLC-ADR | 21.77 | 47.12B |
Related stock screener links
About LBPS
Company Profile
4D Pharma Plc is a pharmaceutical company, which engages in the development of live bio therapeutics. The firm is focused on developing Live Biotherapeutic Products (LBPs), a class of drugs derived from the human gut microbiome. The firm's LBPs are biologics based on live organisms, namely single strains of bacteria. The company has developed MicroRx, its LBP discovery platform. MicroRx interrogates its library of bacterial isolates for therapeutic functionality and characterizes the bacterial isolates using a range of complementary tools and technologies. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) diseases. Its MicroRx enables the discovery of MRx-4DP0004, which is engaged in an ongoing Phase I/II with partly controlled asthma.
Company Info
4D Pharma PLC
9 Bond Court
LEEDS LS1 2JZ GB
CEO: Duncan Peyton
Employees: 95
Phone: 441138950130.0
4D Pharma PLC / LBPS FAQ
What is the stock price of 4D Pharma PLC today?
The current stock price of LBPS is 1.65 null. The price increased by 2.48% in the last trading session.
What is the ticker symbol for 4D Pharma PLC stock?
The exchange symbol of 4D Pharma PLC is LBPS and it is listed on the Nasdaq exchange.
On which exchange is LBPS stock listed?
LBPS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for 4D Pharma PLC stock?
6 analysts have analysed LBPS and the average price target is 7.52 null. This implies a price increase of 356.04% is expected in the next year compared to the current price of 1.65. Check the 4D Pharma PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is 4D Pharma PLC worth?
4D Pharma PLC (LBPS) has a market capitalization of 37.19M null. This makes LBPS a Nano Cap stock.
How many employees does 4D Pharma PLC have?
4D Pharma PLC (LBPS) currently has 95 employees.
What are the support and resistance levels for 4D Pharma PLC (LBPS) stock?
4D Pharma PLC (LBPS) has a resistance level at 2.67. Check the full technical report for a detailed analysis of LBPS support and resistance levels.
Should I buy 4D Pharma PLC (LBPS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LBPS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LBPS, evaluating the profitability, health, valuation and growth aspects
- 4D Pharma PLC (LBPS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- 4D Pharma PLC (LBPS) Sales and EPS estimates to see what analysts future expectations are.
- 4D Pharma PLC (LBPS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- 4D Pharma PLC (LBPS) Insider and Institutional Ownership to learn about the owners and their transactions.
- 4D Pharma PLC (LBPS) Stock Chart to make your own analysis
- 4D Pharma PLC (LBPS) Latest news and press-releases to stay up to date.
Does 4D Pharma PLC (LBPS) stock pay dividends?
LBPS does not pay a dividend.
When does 4D Pharma PLC (LBPS) report earnings?
4D Pharma PLC (LBPS) will report earnings on 2022-09-28.
What is the Price/Earnings (PE) ratio of 4D Pharma PLC (LBPS)?
4D Pharma PLC (LBPS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.24).
LBPS Technical Analysis
LBPS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to LBPS. Both the profitability and financial health of LBPS have multiple concerns.
LBPS Financial Highlights
Over the last trailing twelve months LBPS reported a non-GAAP Earnings per Share(EPS) of -3.24. The EPS decreased by -43.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -10376.92% | ||
| ROA | -125.66% | ||
| ROE | N/A | ||
| Debt/Equity | 0.42 |
LBPS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to LBPS. The Buy consensus is the average rating of analysts ratings from 6 analysts.